MIDDLE EAST AND ASIA PACIFIC ANTIBODY DRUGS MARKET ANALYSIS

Antibodies are proteins made by the immune system that bind to specific markers on cells or tissues. Monoclonal Antibody are a type of antibody made in the laboratory that can be used in the diagnosis or treatment of diseases. In cancer treatment, Monoclonal Antibody may kill cancer cells directly, block the development of tumor blood vessels, or help the immune system kill cancer cells.

The high prevalence of chronic diseases such as cancer, multiple sclerosis, and others and a strong focus of market players on strategic collaborations are the major factors driving the Middle East and Asia Pacific antibody drugs market growth. For instance, in November 2021, CStone Pharmaceuticals, a leading biopharmaceutical company, focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, and Jiangsu Hengrui Pharmaceuticals, a global pharmaceutical company engaged in the research, development, manufacturing and sales of healthcare products, announced a strategic partnership and exclusive licensing agreement on anti-CTLA-4 mAb CS1002 in the Greater China region

The Middle East and Asia Pacific antibody drugs market is estimated to be valued at US$ 43,558.2 Million in 2022 and expected to reach US$ 113,656.9 Million by 2030, witnessing a CAGR of 12.7% over the forecast period (2022-2030).

Figure 1. Middle East and Asia Pacific Antibody Drugs Market Share (%), By Region, 2022

To learn more about this report, request a free sample copy

The high prevalence of chronic diseases such as cancer, multiple sclerosis, and others is expected to drive the growth of the Middle East and Asia Pacific antibody drugs market over the forecast period.

The high prevalence of chronic diseases such as cancer multiple sclerosis, asthma, rheumatoid arthritis, psoriasis, and others in the Middle East and Asia Pacific region is expected to be the major factor driving the growth of the Middle East and Asia Pacific antibody drugs market over the forecast period. For instance, according to an article published by the Journal of Orthopaedic Surgery and Research in August 2020, the age-standardized prevalence of Rheumatoid Arthritis (RA) in the Tibet Autonomous Region (China) in 2020 was estimated to be 6.30%, wherein the prevalence of RA in women was 2.46% and in men was 9.59%.

Figure 2. Middle East and Asia Pacific Antibody Drugs Market Share (%) Analysis, By Disease Indication, 2022

To learn more about this report, request a free sample copy

Strong focus of key players on developing novel antibody drugs is expected to drive the growth of the Middle East and Asia Pacific antibody drugs market over the forecast period.

Bispecific antibodies are artificial proteins that have promising applications in the field of cancer immunotherapy. They are comprised of two Monoclonal Antibody held together by a flexible peptide linker. Key companies operating in the market are focusing on developing bispecific antibody drugs, which is expected to drive the growth of the Middle East and Asia Pacific antibody drugs market over the forecast period. For instance, in December 2021, Janssen Pharmaceutical Companies of Johnson & Johnson (researches, develops, manufactures, and sells pharmaceutical products, medical devices and consumer products)announced updated results from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of talquetamab. Talquetamab is the only investigational off-the-shelf T cell redirecting bispecific antibody in clinical development targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.

Middle East and Asia Pacific Antibody Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries across the globe. The private healthcare sector is one of the sectors which is majorly impacted by the COVID-19 pandemic. The lockdown or shutdown was imposed in various countries which had a negative impact on the economy of the private healthcare sector in the Middle East and Asia Pacific. This lockdown resulted in the closure of industrial establishments, except the manufacturing of essential commodities, and disruption in the supply chain of products. Supply chain and manufacturing activities in countries in the Middle East and Asia Pacific, such as India, China, United Arab Emirates, and others have been disrupted due to the lockdown.

Moreover, countries such as Thailand, Indonesia, Singapore, and others are facing problems with the transportation of raw materials. For instance, according to data published by the Organization for Economic Co-operation and Development (OECD) in November 2020, the COVID-19 has posed major challenges to the healthcare infrastructure in the Middle East region. Some countries including Lebanon have been severely impacted with regard to the overall management of the COVID-19 crisis. Moreover, the OECD stated that countries such as Iran, Syria, Iraq, the Palestinian Authority, and Yemen faced a lack of hospital beds and low COVID-19 testing capacities.

Middle East and Asia Pacific Antibody Drugs Market: Restraint

Adverse effects associated with the use of antibody drugs are expected to act as a restraint for the Middle East and Asia Pacific antibody drugs market growth over the forecast period. According to an article published by the Frontiers in Immunology journal in June 2018, some of the common side effects associated with the use of immunoglobulin therapy (antibody drugs), including headache, flushing, malaise, chills, fever, fatigue, and lethargy, are transient and mild. However, immunoglobulin therapy may also cause adverse effects such as aseptic meningitis, renal impairment, arrhythmia, thrombosis, hemolytic anemia, transfusion-related acute lung injury (TRALI), and others.

Key Players

Major players operating in the Middle East and Asia Pacific antibody drugs market include Novartis AG, Amgen, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Johnson & Johnson Private Limited, AbbVie, Eli Lilly and Company, GlaxoSmithKline plc., Daiichi Sankyo Company, Limited, Celltrion Healthcare Co., Ltd., Mylan N.V., Boehringer Ingelheim International GmbH., Biocon, and Merck & Co., Inc.